


CLINICAL EXPERIENCE WITH BIOSIMILAR FILGRASTIM*



KEY:


- BIOLOGICS INCLUDING BIOSIMILAR MEDICINES
- BIOSIMILAR MEDICINES

MORE CHOICE OF MODERN TREATMENTS

Source: 1 and 2

**BIOSIMILAR MEDICINES:
INCREASED OPTIONS
FOR PHYSICIANS**

MAJOR THERAPY AREAS



Source: 1

CASE STUDY

SWEDEN'S SOUTHERN HEALTHCARE REGION

1 LAUNCH OF BIOSIMILAR FILGRASTIM



2 REDUCTION OF TREATMENT COSTS



3 UPDATED PRESCRIPTION GUIDANCE



NO MORE NEED FOR AGREEMENT
BETWEEN 3 PHYSICIANS TO
PRESCRIBE FILGRASTIM



4 NUMBER OF PATIENTS TREATED INCREASED 5X



MORE AUTONOMY FOR PRESCRIBERS

Source: 3

SOURCE 1: Adapted from European Medicines Agency website (www.ema.europa.eu/ema). **SOURCE 2:** Biopharmaceutical benchmarks 2014, G. Walsh, volumen 32, number 10, October 2014. Nature Biotechnology

SOURCE 3: Adapted from IMS report: delivering on the potential of biosimilar medicines. the role of functioning competitive markets. IMS Institute for Healthcare Informatics. March 2016.

www.imshealth.com/files/web/imshealth_institute/healthcare_briefs/documents/ims_institute_biosimilar_brief_march_2016.pdf

For more information please see consensus information paper Q&A physicians ec.europa.eu/docsroom/documents/8242

* FILGRASTIM IS INDICATED IN THE FOLLOWING THERAPEUTIC AREAS: NEUTROPENIA; FOLLOW-UP OF CANCER TREATMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION (ADAPTED FROM RESPECTIVE EPAR)